


ACTION

#ACC21



Trial Description: Patients admitted with COVID-19 infection were randomized to therapeutic anticoagulation vs. prophylactic anticoagulation. Rivaroxaban 20 mg daily for stable patients & enoxaparin 1 mg/kg twice daily for unstable patients.



RESULTS

- Hierarchical analysis of mortality, duration of hospitalization, and duration of oxygen use through 30 days: 34.8% of the therapeutic anticoagulation group vs. 41.3% of the prophylactic anticoagulation group ($p = \text{nonsignificant}$)
- ISTH major bleeding: 8.4% of the therapeutic anticoagulation group vs. 2.3% of the prophylactic anticoagulation group ($p < 0.05$)

CONCLUSIONS

- Among patients admitted with COVID-19 infection with elevated D-dimer, therapeutic anticoagulation was not superior to prophylactic anticoagulation
- Therapeutic anticoagulation was associated with increased major bleeding

Presented by Dr. Renato D. Lopes at ACC.21